Poseida Therapeutics is a biotechnology business based in the US. Poseida Therapeutics shares (PSTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.71 – a decrease of 15.58% over the previous week. Poseida Therapeutics employs 350 staff and has a trailing 12-month revenue of around $150.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.71 |
|---|---|
| 52-week range | $1.87 - $4.27 |
| 50-day moving average | $2.80 |
| 200-day moving average | $2.98 |
| Wall St. target price | $14.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.63 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.72 from 2024-11-20
| 1 week (2024-11-14) | -15.26% |
|---|---|
| 1 month (2024-10-21) | 8.80% |
| 3 months (2024-08-21) | -6.53% |
| 6 months (2024-05-21) | -8.42% |
| 1 year (2023-11-21) | 4.21% |
|---|---|
| 2 years (2022-11-21) | -34.62% |
| 3 years (2021-11-19) | 7.6 |
| 5 years (2019-11-18) | N/A |
| Revenue TTM | $150.9 million |
|---|---|
| Operating margin TTM | 27.52% |
| Gross profit TTM | $-22,407,000 |
| Return on assets TTM | -13.11% |
| Return on equity TTM | -57.63% |
| Profit margin | -40.28% |
| Book value | $0.90 |
| Market Capitalization | $312.9 million |
TTM: trailing 12 months
We're not expecting Poseida Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Poseida Therapeutics's shares have ranged in value from as little as $1.87 up to $4.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Poseida Therapeutics's is 0.536. This would suggest that Poseida Therapeutics's shares are less volatile than average (for this exchange).
Poseida Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.